Patent intelligence · US
US 9220692
Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
Patent details — US 9220692
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 29, 2015
- Expiration
- Dec 24, 2035
- Applicant
- TEVA WOMEN'S HEALTH, INC.
- Claims
- 19
- CPC classes
- A61K, A61K31/00, A61K31/137, A61K31/465
Quick answer
US 9220692 (Methods of reducing symptoms in subjects using single dosage forms with tapering release rates) is held by TEVA WOMEN'S HEALTH, INC.. Status: granted. Granted Dec 29, 2015. Expires Dec 24, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA WOMEN'S HEALTH, INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K31/00, A61K31/137, A61K31/465, A61K31/515, A61K31/522
More from TEVA WOMEN'S HEALTH, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 9220692?
US 9220692 (Methods of reducing symptoms in subjects using single dosage forms with tapering release rates) is held by TEVA WOMEN'S HEALTH, INC.. Status: granted. Granted Dec 29, 2015. Expires Dec 24, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9220692?
TEVA WOMEN'S HEALTH, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 9220692 expire?
Our index shows an expiration date of Dec 24, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.